Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexfenfluramine hydrochloride: an anorexigenic agent

K A Bever1, P J Perry

  • 1College of Pharmacy, University of Iowa, Iowa City 52242-0123, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|October 6, 1997
PubMed
Summary

Dexfenfluramine hydrochloride effectively aids weight loss in obese patients, but its benefits diminish after six months. It may also help manage other conditions but carries risks like insomnia and pulmonary hypertension.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System.

Human & experimental toxicology·2015
Same author

Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.

Acta psychiatrica Scandinavica·2006
Same author

Therapeutic drug monitoring of antipsychotics.

Psychopharmacology bulletin·2002
Same author

DNA tetraplex-binding drugs: structure-selective targeting is critical for antitumour telomerase inhibition.

Mini reviews in medicinal chemistry·2002
Same author

The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1.

British journal of cancer·2002
Same author

Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists·2002

Area of Science:

  • Pharmacology and Therapeutics
  • Obesity Management

Background:

  • Dexfenfluramine hydrochloride is the dextrorotatory isomer of fenfluramine.
  • It is indicated for obesity management in patients with a body mass index (BMI) of ≥30 kg/m2 or ≥27 kg/m2 with risk factors.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of dexfenfluramine hydrochloride.

Main Methods:

  • Review of pharmacology, pharmacokinetics, efficacy, and adverse effects.
  • Analysis of randomized, placebo-controlled trials.

Main Results:

  • Dexfenfluramine is a pure serotonin agonist with 68% systemic bioavailability, metabolized in the liver.
  • Effective weight reduction observed in trials of 3-6 months; significant loss occurred between months 4-6 in a one-year trial.

Related Experiment Videos

  • Potential benefits include reduced blood pressure, glycosylated hemoglobin, blood glucose, and lipids; also considered for eating disorders and other conditions.

    • Conclusions:

    • Dexfenfluramine hydrochloride is effective for selected obese patients, primarily as an adjunct to diet and exercise.
    • Efficacy wanes after six months of continuous use.
    • Frequent adverse effects include insomnia, diarrhea, and headache; risk of serotonin syndrome with combined serotonergic agonists and primary pulmonary hypertension.